Let’s start up with the current stock price of Cytosorbents Corporation (CTSO), which is $6.13 to be very precise. The Stock rose vividly during the last session to $6.84 after opening rate of $6.84 while the lowest price it went was recorded $6.095 before closing at $6.93.Recently in News on October 12, 2021, CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery. The U.S. STAR-D and already recruiting STAR-T randomized controlled pivotal trials are intended to establish DrugSorb-ATR as a single, easy-to-use solution for the reduction of perioperative bleeding in open heart surgery patients caused by the most widely prescribed next generation antiplatelet and anticoagulant drugs. You can read further details here
Cytosorbents Corporation had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $11.68 on 02/04/21, with the lowest value was $6.09 for the same time period, recorded on 10/13/21.
Cytosorbents Corporation (CTSO) full year performance was -30.89%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Cytosorbents Corporation shares are logging -47.54% during the 52-week period from high price, and -6.27% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $6.54 and $11.68.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1040757 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Cytosorbents Corporation (CTSO) recorded performance in the market was -23.09%, having the revenues showcasing -20.08% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 268.25M, as it employees total of 195 workers.
Market experts do have their say about Cytosorbents Corporation (CTSO)
During the last month, 6 analysts gave the Cytosorbents Corporation a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 8.02, with a change in the price was noted -2.30. In a similar fashion, Cytosorbents Corporation posted a movement of -27.28% for the period of last 100 days, recording 266,345 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CTSO is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Cytosorbents Corporation (CTSO)
Raw Stochastic average of Cytosorbents Corporation in the period of last 50 days is set at 0.94%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 1.27%. In the last 20 days, the company’s Stochastic %K was 11.34% and its Stochastic %D was recorded 17.69%.
Bearing in mind the latest performance of Cytosorbents Corporation, several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -23.09%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -34.93%, alongside a downfall of -30.89% for the period of the last 12 months. The shares increased approximately by -23.18% in the 7-day charts and went up by -26.32% in the period of the last 30 days. Common stock shares were lifted by -20.08% during last recorded quarter.